SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition

On August9, 2017, SciClone Pharmaceuticals, Inc. issued a press release announcing final financial results for the second quarter ended June 30, 2017. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein in its entirety.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) The following exhibits are filed herewith:

Exhibit 99.1

Press release dated August 9, 2017


SCICLONE PHARMACEUTICALS INC Exhibit
EX-99.1 2 scln-20170809xex99_1.htm EX-99.1 Exhibit 991 Q217 Financial Results Exhibit 99.1  Corporate Contacts     Wilson W. Cheung Jane Green Chief Financial Officer Investors/Media 650.358.3434 650.358.1447 [email protected] [email protected]  SCICLONE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS   FOSTER CITY,…
To view the full exhibit click here

About SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company’s development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).